Trial Profile

A phase III trial of Nefecon in Japanese patients with IgA nephropathy (IgAN)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Budesonide (Primary)
Indications IgA nephropathy
Focus Therapeutic Use

Most Recent Events

29 Jun 2026 Primary endpoint has been met according to a Viatris media release.
29 Jun 2026 Status changed from planning to completed as per a Viatris media release.
29 Jun 2026 According to a Viatris media release, company is targeting submission of a New Drug Application in Japan by the end of 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com